Mechanism of cisplatin induced hypomagnesemia

Mechanism of cisplatin induced hypomagnesemia - Cisplatin hypomagnesemia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33071

Enrollment

Registered

2010-01-14

Start date

2009-09-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

electrolytstoornissen Hypomagnesemia = low serum magnesium concentration

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All oncological patients who are selected for monotherapy with cisplatin.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
Factors associated with hypomagnesemia, including 24-hour urinary magnesium, erythrocyte magnesium levels, 17-β-estradiol, endothelial growth factor, acid-base balance.	—

Secondary

Measure	Time frame
Differences between patients with and without hypomagnesemia (patient characteristics, underlying disease, chemotherapy characteristics, laboratory values)	—

Countries

Netherlands

Outcome results